{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:15:41Z","timestamp":1788455741648,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>This meta-analysis was exerted in assessing the anticancer efficacy and safety of nab-paclitaxel (nab-P) when combined with platinum compound agents for therapy in patients with non-small cell lung cancer (NSCLC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We systematically searched the following seven electronic databases: PubMed, Cochrane Library, Web of Science, Embase, CNKI, Wan Fang, and China Science and Technology Journal Data. Randomized comparative clinical [randomized controlled clinical trial (RCT)] studies on nab-P plus platinum and carboplatin or cisplatin in combination with conventional chemotherapy agents or traditional paclitaxel were searched.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 19 RCT studies involving 6,011 patients were analyzed. The primary outcome includes the overall response rate (ORR), overall survival (OS), and progression-free survival (PFS). The secondary outcome includes adverse events (AEs). Nab-P combined with platinum (carboplatin\/cisplatin) had a better ORR [odds ratio (OR) = 1.66, 95% confidence interval (CI) (1.34, 2.05), <jats:italic>p<\/jats:italic> &amp;lt; 0.001] and improved PFS [hazard ratio (HR) = 0.84, 95% CI: (0.74, 0.94), <jats:italic>p<\/jats:italic> = 0.01] and OS [HR = 0.86, 95% CI: (0.78, 0.96), <jats:italic>p<\/jats:italic> = 0.008] in NSCLC patients. ORR [OR = 2.18, 95% CI: (1.07, 4.43)], PFS [HR = 0.62, 95% CI: (0.40, 0.97)], and OS [HR = 0.63, 95% CI: (0.49, 0.81)] were significantly improved among patients aged &amp;gt;70 years, and ORR [OR = 1.80, 95% CI: (1.20, 2.70)] and PFS [HR = 0.74, 95% CI: (0.56, 0.97)] were significantly elevated with SCC rate \u226565% in NSCLC patients (all <jats:italic>p<\/jats:italic> &amp;gt; 0.05). Among the adverse effects, the prevalence of neutropenia, neuralgia, and arthralgia\/myalgia (\u2265 grade 3) compared to that of the control group. On the other hand, the prevalence of anemia and thrombocytopenia was higher in the nab-P plus platinum (carboplatin\/cisplatin) compared to that of controls. It is worth noting that fatigue did not show statistical significance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Nab-P in combination with carboplatin\/cisplatin regimen improves efficacy and tolerability in patients with NSCLC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>http:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>, identifier: CRD42022288499.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1139248","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T14:14:35Z","timestamp":1690208075000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Tianying","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghui","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingling","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianbao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Ann Glob Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Prim."},{"key":"B4","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.2012.46.9270","article-title":"New pathologic classification of lung cancer: relevance for clinical practice and clinical trials","volume":"31","author":"Travis","year":"2013","journal-title":"J Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/jnci\/djk196","article-title":"Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis","volume":"99","author":"Ardizzoni","year":"2007","journal-title":"J Natl Cancer Inst."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.6004\/jnccn.2012.0130","article-title":"Non-small cell lung cancer","volume":"10","author":"Ettinger","year":"2012","journal-title":"J Natl Compr Canc Netw."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/annonc\/mdu123","article-title":"2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line\/second and further lines of treatment in advanced disease","volume":"25","author":"Besse","year":"2014","journal-title":"Ann Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"Nab-P mechanisms of action and delivery","volume":"170","author":"Yardley","year":"2013","journal-title":"J Control Rel."},{"key":"B9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J Control Rel."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"L187","DOI":"10.1152\/ajplung.00152.2002","article-title":"Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer","volume":"284","author":"John","year":"2003","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7453","DOI":"10.7314\/APJCP.2014.15.17.7453","article-title":"Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III\/IV squamous non-small cell lung cancer","volume":"15","author":"Fang","year":"2014","journal-title":"Asian Pacific J Cancer Prev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/bjc.2015.181","article-title":"Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel","volume":"113","author":"Langer","year":"2015","journal-title":"Br J Cancer."},{"key":"B14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.cllc.2014.09.003","article-title":"Weekly nab-P in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment","volume":"16","author":"Langer","year":"2015","journal-title":"Clin Lung Cancer."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1093\/annonc\/mdt235","article-title":"Safety and efficacy analysis by histology of weekly nab-P in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer","volume":"24","author":"Socinski","year":"2013","journal-title":"Ann Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/annonc\/mds461","article-title":"Safety and efficacy of weekly nab\u00ae-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer","volume":"24","author":"Socinski","year":"2013","journal-title":"Ann Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-P in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J Clin Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lungcan.2013.02.020","article-title":"Efficacy and safety of weekly nab-P plus carboplatin in patients with advanced non-small cell lung cancer","volume":"81","author":"Satouchi","year":"2013","journal-title":"Lung Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.cllc.2016.04.002","article-title":"Weekly nab-P in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with diabetes","volume":"17","author":"Hirsh","year":"2016","journal-title":"Clin Lung Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ejca.2019.01.007","article-title":"A randomised phase II clinical trial of nab-P and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002)","volume":"109","author":"Wang","year":"2019","journal-title":"Eur J Cancer"},{"key":"B21","unstructured":"Clinical efficacy of albumin-bound paclitaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer (in Chinese)812\n            XieY\n            WangB-Q\n          28883517Clin Res.292021"},{"key":"B22","unstructured":"Paclitaxel liposome combined with cisplatin versus albumin-bound paclitaxel combined with cisplatin as first-line treatment for advanced non-small cell lung cancer (in Chinese)3246\n            GaoY\n            ZhuZ-T\n          J Nanchang Univ542014"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.19613\/j.cnki.1671-3141.2018.100.097","article-title":"Albumin paclitaxel in combination with platinum versus gemcitabine in combination with platinum in first-line treatment Efficacy and safety analysis of advanced squamous lung cancer (in Chinese)","volume":"18","author":"Zhu","year":"2018","journal-title":"World Lat Med Inform."},{"key":"B24","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3969\/j.issn.2095-1264.2022.06.14","article-title":"Clinical effects of albumin-bound paclitaxel combined with carboplatin in the treatment of advanced non-small cell lung cancer (in Chinese)","volume":"12","author":"Chen","year":"2022","journal-title":"Anti-tumor Pharm"},{"key":"B25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.21147\/j.issn.1000-9604.2019.02.08","article-title":"Weekly albumin-bound paclitaxel\/cisplatin versus gemcitabine\/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: a phase II open-label clinical study","volume":"31","author":"Qin","year":"2019","journal-title":"Chin J Cancer Res Apr."},{"key":"B26","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs. chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"J Am Med Assoc Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e791","DOI":"10.1016\/S2666-7568(21)00255-5","article-title":"Efficacy and safety of carboplatin with nab-P versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial","volume":"2","author":"Kogure","year":"2021","journal-title":"Lancet Healthy Longev Dec."},{"key":"B28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.19347\/j.cnki.2096-1413.202202008","article-title":"Clinical effect of albumin-bound paclitaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer (in chinese)","volume":"7","author":"Su","year":"2022","journal-title":"Clin Med Res Practice."},{"key":"B29","unstructured":"Clinical efficacy of albumin-bound paclitaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer (in chinese)83\n            WangY-J\n            WangG-F\n            NiX-Q\n          28883517Chang Shou20212021"},{"key":"B30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3969\/j.issn.2095-7629.2020.16.044","article-title":"Effectiveness and safety of cisplatin combined with gemcitabine versus combined albumin-bound paclitaxel in the treatment of advanced non-small cell lung cancer (in chinese)","volume":"18","author":"Cao","year":"2020","journal-title":"Contemp Med Symp."},{"key":"B31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/21691401.2018.1552595","article-title":"Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis","volume":"47","author":"Tan","year":"2019","journal-title":"Artif Cells Nanomed Biotechnol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"10760","DOI":"10.1038\/s41598-017-11404-9","article-title":"Nab-P in combination with cisplatin versus docetaxel plus cisplatin as first-line therapy in non-small cell lung cancer","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12885-020-6588-y","article-title":"A phase I\/II study of weekly nab-P plus cisplatin in chemotherapy-na\u00efve patients with advanced non-small-cell lung cancer","volume":"20","author":"Hattori","year":"2020","journal-title":"BMC Cancer."},{"key":"B34","unstructured":"Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel103844\n            IbrahimNK\n            DesaiN\n            LeghaS\n            Soon-ShiongP\n            TheriaultRT\n            RiveraE\n          12006516Clin Cancer Res.82002"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-P is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J Clin Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0242","article-title":"nab-P potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer","volume":"2","author":"Frese","year":"2012","journal-title":"Cancer Discov."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1139248\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T14:14:52Z","timestamp":1690208092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1139248\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":36,"alternative-id":["10.3389\/fmed.2023.1139248"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1139248","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"article-number":"1139248"}}